Dissolution improvement of solid self-emulsifying drug delivery systems of fenofi brate using an inorganic high surface adsorption material
technology conversion) such as solid self-emulsifying systems. They are designed to increase the solubility and bioavailability of drugs belonging to the BCS classes II and IV, in which the dissolution rate is the limiting factor for absorption (5) (6) (7) (8) . Lipid-based carriers are usually liquid at room temperature and are generally encapsulated into so /hard gelatin capsules for fi nal oral delivery. This could be a great challenge since the interaction between the liquid formulation and capsule shell may result in either bri leness or soness of the shell (9) . In addition, the stability of liquid formulations could be another major issue (e.g. leaching and rancidity), since some drugs might suff er signifi cant chemical instability in both aqueous and oily formulations.
To address this limitation, incorporation of liquid lipid formulations into a solid dosage form is therefore convincing and desirable. Liquid lipid formulations could be transformed into acceptable free fl owing powder by loading the formulation onto a suitable solid carrier (10, 11) . Solid dispersions and in particular self-emulsifying drug delivery systems (SEDDS) have proved to be the most practical route to commercialization. Success of Fortovase ® (Saquinavir), Norvir ® (Ritonavir) and Neoral ® cyclosporine as lipid suspensions have prompted formulators to develop more stable forms by converting these suspensions into powder (12) . Neusilin ® 's high specifi c area, increased surface adsorption, porosity, anticaking, fl ow enhancing properties and its ability to keep the drug stable under amorphous state make it one of the best choices among the adsorbents available today (13) . Good understanding of the characteristics of lipid excipients and their performance in formulations is desirable to rank and select suitable excipients in formulation development.
Fenofi brate is a lipid-regulating agent that has chemical, pharmacological, and clinical similarities to other fi brate drugs such as clofi brate and gemfi brozil (14) . Fenofi brate is a BCS class II drug with a high dose number (15) . It can be assumed that the low oral bioavailability of fenofi brate is due to its solubility and dissolution limitations. It is a nonelectrolyte with low aqueous solubility (< 3 µg mL -1 ) and fairly high octanol/water partition coeffi cient (log P 4.6).
Eff orts to develop tablet formulations containing suffi cient quantities of lipid and surfactant excipients to solubilize poorly soluble drugs have met with limited success due to the tendency of these excipients to compromise the physical integrity and mechanical strength of conventional compressed tablets. To achieve extensive absorption of a poorly water soluble compound from the GI tract requires an innovative formulation approach. Encapsulation of formulations such as liquids or semi-solids provides opportunities for delivering poorly water-soluble compounds with reproducible absorption and acceptable bioavailability.
While an enormous amount of industrial interest exists in transforming such liquid lipid formulations into free-fl owing powders that are compatible with direct tablet pressing, only a limited number of studies have been conducted to investigate the solidifi cation of lipid formulations; they have been focused on their adsorption onto inorganic high surface area materials. The goal of the current research is to assess how the adsorption of drug loaded SEDDS/SNEDDS onto an inorganic high surface area material (Neusilin ® grade US2) aff ects its in vitro (dissolution) performance. ganic high surface adsorption material, Acta Pharm. 65 (2015) 29-42.
EXPERIMENTAL

Materials
All chemicals used in the studies were obtained from commercial suppliers. Fenofibrate (2-[4-(4-chlorobezoyl) phenoxy]-2-methylpropionic acid 1-methylethyl ester) was supplied by Sigma-Aldrich Co, USA. Miglyol 812 (M812), Imwitor 988 (I988), Imwitor 308 (I308) and propylene glycol (PG, 98 % pure) were supplied by Sasol Germany GmbH, Germany. The non-ionic surfactants used were TO-106V (PEG 6 sorbitan monooleate, HLB-10) and HCO-30 (PEG 30 hydrogenated castor oil, HLB-11), supplied by Nikko Chemicals Co., Japan. All excipients were used without further purifi cation. Cremophor EL (CrEL, polyoxyethylene 35 castor oil), and Cremophor RH40 (CrRH40, polyoxyethylene 40 castor oil) were from Sigma Chemical Co. (USA). Neusilin ® grade US2 (NUS2, synthetic magnesium aluminometasilicate, Fuji Chemical Co., Japan) was used as the microporous adsorbent to load SEDDS/SNEDDS. Lipanthyl ® (marketed product of fenofi brate, 200 mg micronized capsule) manufactured by Abbo (USA) was used in the study. Water used in this study was obtained from a Milli-Q water purifi cation system (Sartorius, Germany). All other chemicals and solvents were of analytical purity.
Methods
Design of liquid SEDDS/SNEDDS. -Within the current scope of the study, self-emulsifying lipid formulations, particularly SEDDS/SNEDDS, have been developed using lipid formulation classifi cation systems (LFCS). LFCS was proposed by Pouton in 2000 in four categories (16) to gain knowledge of excipient selection and compare the performance of various lipid-based drug delivery systems. Hence, LFCS type IIIA and IIIB lipid-based formulations (SEDDS/SNEDDS) have been prepared in two component systems with varying oil and surfactant concentrations. For systems which involved a blend of two oils with a surfactant, the strategy was to weigh and combine a primary mixture of the two oil components. For example, a mixture of M812 and I988 (7:3, by mass) was prepared and then blended with 50 % surfactant. The mixture was thoroughly blended with a Vm1 vortex (Ratek Instruments Pty. Ltd., Victoria, Australia), with heating if necessary, to ensure uniformity. The formulations were prepared using 5-g capacity vials and were tightly sealed until further use.
Droplet size distribution of liquid SEDDS/SNEDDS. -The droplet size distribution of diluted SEDDS/SNEDDS was measured by laser diff raction analysis using Zetasizer (Nano ZS, Germany) particle sizing systems (17) . The formulations were diluted at a ratio of 1:1000 V/V (SEDDS/SNEDDS : distilled water) and mixed for 1 min before analysis. Samples were placed directly into the module and measured 10 times. Particle size was calculated from the volume size distribution. All experiments were performed in triplicate and good agreement was found between measurements. As reported earlier, the self-emulsifying effi ciency is strongly associated with the mean droplet size of the produced emulsion (18, 19) .
Preparation of solid SEDDS/SNEDDS. -The liquid SEDDS/SNEDDS was added gradually and blended with the adsorbent NUS2 at the following fi xed fi nal SEDDS/SNEDDS to adsorbent appropriate mass ratio of 50/50, 60/40 and 70/30 (%, m/m). Briefl y, a fi xed amount of liquid SEDDS/SNEDDS was initially added to and mixed with NUS2 (20) . The batch size of each blend was varied according to the quantity of the adsorbent and was categorized based on the fl owability of the powder. The fl ow behaviour of the adsorbed blend was assessed visually only to measure if a non-fl owing cohesive mass was formed.
Characterization of solid SEDDS/SNEDDS powder. -Particle size, shape and bulk density aff ect the fl owability of powder material. The angle of repose for the solid SEDDS/ SNEDDS was measured to determine the fl owability of the powder (21) . Briefl y, a glass funnel was fi ed at a fi xed height (H) and its tip was distanced from wax paper placed on a horizontal surface. Solid powder was transferred through the funnel to the surface until the apex of the conical pile reached the tip of the funnel. The test result was calculated as follows:
angle of repose = tan α = H/r where r is the radius of the conical pile and α is the angle of repose. 
X-ray diff raction (XRD)
. -Powder crystallinity was assessed by a multipurpose X-ray diff ractometer (Ultima IV, Rigaku, Japan). The samples were analyzed using CuKα radiation of wavelength 1.54056 Å, generated at 40 kV voltage, 40 mA current and receiving slit of 0.3 mm. Analyses were preformed over 2θ range of 3-60° with an angular increment of 0.5° min and scan step time of 1.0 s.
Diff erential scanning calorimetry (DSC)
. -DSC analyses of powdered samples were conducted using DSC-60, Shimadzu, Japan. The samples (3-5 mg) were hermetically sealed in aluminum pans and heated at a scanning rate of 10 °C min -1 under dry nitrogen fl ow (30 mL min -1 ) over a temperature range of 0-200 °C. Pure water and indium standard were used to calibrate the DSC temperature and enthalpic scale. Data from the thermal analysis were recorded using the Shimadzu so ware program in a TA 50I PC system.
Scanning electron microscopy (SEM).
-Surface morphology of the raw drug, NUS2 and solid SEDDS/SNEDDS powder was visualized by SEM (Jeol JSM 5400LV SEM, Japan) operated at 15 kV. The samples were spu er-coated with a thin gold (SPI spu er coater, PA19380, USA) palladium layer under an argon atmosphere in a high vacuum evaporator and images were then acquired from the system.
In vitro dissolution studies. -The in vitro dissolution studies of the representative solid SEDDS/SNEDDS powder were fi lled in capsules (size 0) for the experiment. Dissolution of solid SEDDS/SNEDDS, pure fenofi brate powder and the marketed fenofi brate capsule (200 mg Lipanthyl) was monitored using an automated dissolution tester (Logan Instrument Corp, USA) coupled to an automated sample collector (SP-100 peristaltic pump Logan). The standard USP II (apparatus 2) (paddle type, Model UDT-804, Logan) paddle method was used at 50 rpm and 37 ± 0.5 °C. Dissolution media (900 mL) of pH 1.2 and pH 7.4 were selected to mimic the physiological pH of the GIT. Samples were collected periodically a er 15, 30, 45, 60, 90, and 120 min and replaced by freshly prepared dissolution medium. A er fi ltration through a microfi lter (0.45 µm), fenofi brate in the withdrawn samples was analyzed at 288 nm by UHPLC (Dionex, ultimate 3000, Thermo Scientifi c, USA) using an appropriate solvent. Chromatographic separation was performed on a reversed-phase Acquity ® BEH C 18 column (1.7 µm particle size, 50 mm × 2.1 mm ID) at 30 ˚C with an isocratic elution profi le. The mobile phase consisting of ethanol and water (70:30, %, V/V) at a fl ow rate of 0.3 mL min -1 was used. All experiments were carried out in triplicate.
RESULTS AND DISCUSSION
Composition of lipid-based SEDDS/SNEDDS systems using various concentrations of oil and surfactant are presented in Table I . There are most interesting formulation systems within the lipid formulation classifi cation systems (LFCS), which are likely to produce nanoparticle formulations.
Droplet size analysis of liquid SEDD. -Self-emulsifi cation of mixtures containing medium chain mono/di/tri-glycerides [M812:I988 (7:3)] with water insoluble surfactant (TO-106V and/or HCO-30) showed the particle size above 50 nm, and were thus represented as SEDDS (Table II) . On the other hand, similar oil compositions [M812:I988 (7:3)] with water soluble surfactant (CrEL and or CrRH40) showed a particle size lower than 50 nm, and were represented as SNEDDS (Table II) . The apparent particle size distributions of polar oil I308 with all the representative surfactants in the formulations were found to be lower than 50 nm (Table II) , producing nanodispersions at surfactant concentrations of 50 %; the dispersion nature of all the formulations was homogeneous upon aqueous dilution even though SNEDDS3 and SNEDDS4 produced more heterogeneous particles, which was shown by the higher PDI values (see Table II ). However, oil and surfactant used in both 
Analyses of solid SEDDS
Particle size determination of solid SEDDS. -The z-average diameter and volume mean distribution of the solid SEDDS/SNEDDS powder, according to the percentage of adsorbent NUS2 added in the liquid formulations, are presented in Table III . The z-average diameter was measured a er the solid powder was dispersed in water and then fi ltered (using a 0.22-µm fi lter). In most of the formulation systems, the particle size was reduced with the increase in NUS2 content. In addition, it was found by visual determination that the use of 50 % NUS2 showed good fl owability of the powders.
Measurement of the angle of repose. -In the current studies, ratios of liquid SEDDS/ SNEDDS to NUS2 of 1:1, 1.5:1, and 2.3:1 produced dry free fl owing powders. There were no substantial changes between these ratios due to the high adsorption capacity of the adsorbent (NUS2) and retention of liquid SEDDS/SNEDDS in their intra-particular pores. On visual inspection, all powders were dry and free flowing at this point. However, the liquid SEDDS/SNEDDS-to-NUS2 ratios of 1:1 and 1.5:1 were be er than 2.3:1 (Table IV) . This suggests that the selection of 1.5:1 ratio would be ideal for good fl owability of the solid SEDDS/ SNEDDS powder and high drug loading for fenofi brate.
X-ray diff raction analysis. -XRD studies were performed to justify the physical nature of the drug in solid SEDDS/SNEDDS formulations. Fig. 1 depict the XRD spectra of pure fenofi brate, NUS2 and the representative solid SEDDS/SNEDDS formulations. Pure fenofi brate showed sharp peaks in the spectra, which were obtained at 13.79, 15.21, 20.05, 22.58, 31.76, and 50.12 °C (2θ), due to the native crystalline form of the drug. There were no peaks in NUS2 and representative SEDDS/SNEDDS formulations. Hence, the disappearance of drug peaks in the representative solid SEDDS/SNEDDS formulations established the presence of fenofi brate in amorphous form.
Diff erential scanning calorimetry (DSC). -
The generated DSC thermograms of pure fenofi brate, adsorbent NUS2, and the representative solid SEDDS/SNEDDS formulations are a Liquid SEDDS/SNEDDS, 1:1000 dilutions in water. b NUS2 was used at various ratios in the lipid formulation and fenofi brate was loaded at 80 % of equilibrium solubility. c Mean, n = 3; RSD < 10 %. shown in Fig. 2 . A sharp endothermic peak of pure fenofi brate was observed at 81.25 °C. However, there were no peaks for NUS2 and solid SEDDS/SNEDDS formulations. This suggests that fenofi brate converted from crystalline to amorphous state during the preparation of solid SEDDS/SNEDDS using NUS2.
Scanning electron microscopy. -The scanning electron micrographs in Fig. 3a showed fenofi brate as a crystalline powder with irregularly shaped crystals. Surface morphology of the NUS2 and solid SEDDS/SNEDDS formulations shown in Figs. 3b-e was found homogeneous, uniform and smooth. Regarding the release of fenofi brate from formulations F1, F2 and F7, it was found that formulation F1 (50 % NUS2) showed higher release than formulations F2 and F7. This is evident from the similar results obtained when comparing fenofi brate release from F5, F6 and F9 (Fig. 4c) .
The overall comparison of the in vitro dissolution profi les of fenofi brate from all solid SEDDS/SNEDDS (except F1, F2 and F7) was over 50 % in 60 min and was signifi cantly higher than the release from the control and marketed product Lipanthyl ® (15 %). In case of formulations F1, F2 and F7, the drug release was lower or delayed, which could be due to the water insoluble surfactant used in designing liquid SEDDS1 [(M812:I988 (7:3)/TO106V (1/1)]. The overall results of all the solid SEDDS/SNEDDS showed that the maximum percentage of drug release was achieved within 15 min.
On the other hand, in vitro dissolution studies performed in the basic medium (pH 7.4 shown in Figs. 5a-c for the same formulations F1-F9, fenofi brate raw powder and Lipanthyl ® are presented in Fig. 3 . In case of formulations F1, F2 and F7, the drug release was faster and the dissolution effi ciency was higher compared to the control and Lipanthyl ® . Cumulative percentage release from solid SEDDS (F1) was found to be more than 45 %, within 60 min and was signifi cantly higher than that of the control and Lipanthyl ® (17 %). From the overall release data in the slightly basic medium it followed that all the formulations (F1-F9) showed higher release rate of fenofi brate compared to fenofi brate raw powder and Lipanthyl ® . In all cases of the solid SEDDS/SNEDDS, almost 45 % of the drug was released within 15 min during the studies. Within all solid formulations, the use of 50 % NUS2 (F1, F3 and F5) gave be er fenofi brate release profi les.
The overall drug release profi le of solid SEDDS and SNEDDS in the current investigation showed that all the developed formulations (F1-F9) had higher drug release profi les 
CONCLUSIONS
A large surface area material NUS2 with exceptional excipient properties for improving drug delivery was used as the microporous adsorbent to load SEDDE/SNEDDS. The solid state characterization studies indicate that the SEDDS2 and SNEDDS3 [(M812:I988 (7:3)/HCO30 (1/1), I308/HCO30 (1/1)] using 40-50 % NUS2 proved to be free fl owing fi ne powders in stable form and the potential systems for high drug loading.
All the solid SEDDS/SNEDDS showed enhanced dissolution profi le, compared to both fenofi brate raw powder and Lipanthyl ® . Solid state characterization employing the SEM, XRD and DSC studies indicated that the SEDDS/SNEDDS powder produced smooth granular particles in amorphous form.
In conclusion, solidifi cation using adsorbents is a powerful technique for the preparation of rapidly dissolving formulations of fenofi brate. The solidifi cation of SEDDS/SNEDDS using NUS2 improved the surface adsorption, porosity, anticaking fl ow enhancing properties and the ability to keep the drug stable in amorphous state, which could be one of the best carriers today to deliver poorly soluble drugs.
This approach could potentially lead to be er bioavailability of fenofi brate drug products. Conversion of a liquid self-emulsifying drug delivery system into a free fl owing solid powder using high surface inorganic materials (Neusilin US2) is one of the most recent and promising approaches in pharmaceutical dosage systems. However, knowledge of the integrity of excipients is helpful in this regard, but it is ultimately necessary to test each formulation.
The infl uence of »drug-adsorbent formulation« interactions should be investigated on the case-by-case basis in any formulation.
